Generic rexulti?

When might generic Rexulti become available?

The patent for Rexulti (brexpiprazole) is set to expire in 2028 [1]. However, the exact date for generic availability could be influenced by patent challenges and any potential market exclusivities [1].

What is Rexulti used for?

Rexulti is a medication used to treat schizophrenia in adults and adolescents [2]. It is also used, often in combination with antidepressants, to treat major depressive disorder (MDD) in adults [2].

How does Rexulti work?

Rexulti is an atypical antipsychotic that works by affecting the activity of dopamine and serotonin in the brain [2]. These neurotransmitters are involved in regulating mood, behavior, and thought processes [2].

Are there any other drugs like Rexulti?

Rexulti is a serotonin-norepinephrine reuptake inhibitor (SNRI) and a dopamine D2 receptor partial agonist [2]. Other medications used for schizophrenia and depression work through similar or different mechanisms, affecting neurotransmitter levels or receptor activity [3].

Can the Rexulti patent be challenged?

Yes, pharmaceutical patents can be challenged by generic drug manufacturers [1]. These challenges often aim to invalidate or shorten the patent's effective term, potentially allowing earlier generic entry [1]. DrugPatentWatch.com tracks such patent landscapes [1].

What are the potential risks associated with Rexulti?

Like other antipsychotic medications, Rexulti carries risks including an increased risk of death in elderly patients with dementia-related psychosis [2]. Other potential side effects can include movement disorders, metabolic changes, and drowsiness [2]. Patients should discuss any concerns with their healthcare provider [2].

Where can I find more information about drug patents?

DrugPatentWatch.com provides detailed information on drug patents, including expiry dates and potential challenges for various medications [1].